2g44
|
Human Estrogen Receptor Alpha Ligand-Binding Domain In Complex With OBCP-1M-G and A Glucocorticoid Receptor Interacting Protein 1 NR Box II Peptide
OverviewOverview
Estrogen receptors alpha (ERalpha) and beta (ERbeta) have distinct, functions and differential expression in certain tissues. These, differences have stimulated the search for subtype-selective ligands., Therapeutically, such ligands offer the potential to target specific, tissues or pathways regulated by one receptor subtype without affecting, the other. As reagents, they can be utilized to probe the physiological, functions of the ER subtypes to provide information complementary to that, obtained from knock-out animals. A fluorescence resonance energy, transfer-based assay was used to screen a 10,000-compound chemical library, for ER agonists. From the screen, we identified a family of, ERbeta-selective agonists whose members contain bulky oxabicyclic, scaffolds in place of the planar scaffolds common to most ER ligands., These agonists are 10-50-fold selective for ERbeta in competitive binding, assays and up to 60-fold selective in transactivation assays. The weak, uterotrophic activity of these ligands in immature rats and their ability, to stimulate expression of an ERbeta regulated gene in human U2OS, osteosarcoma cells provides more physiological evidence of their, ERbeta-selective nature. To provide insight into the molecular mechanisms, of their activity and selectivity, we determined the crystal structures of, the ERalpha ligand-binding domain (LBD) and a peptide from the, glucocorticoid receptor-interacting protein 1 (GRIP1) coactivator, complexed with the ligands OBCP-3M, OBCP-2M, and OBCP-1M. These structures, illustrate how the bicyclic scaffolds of these ligands are accommodated in, the flexible ligand-binding pocket of ER. A comparison of these structures, with existing ER structures suggests that the ERbeta selectivity of OBCP, ligands can be attributed to a combination of their interactions with, Met-336 in ERbeta and Met-421 in ERalpha. These bicyclic ligands show, promise as lead compounds that can target ERbeta. In addition, our, understanding of the molecular determinants of their subtype selectivity, provides a useful starting point for developing other ER modulators, belonging to this relatively new structural class.
DiseaseDisease
Known diseases associated with this structure: Atherosclerosis, susceptibility to OMIM:[133430], Breast cancer OMIM:[133430], Estrogen resistance OMIM:[133430], HDL response to hormone replacement, augmented OMIM:[133430], Migraine, susceptibility to OMIM:[133430], Myocardial infarction, susceptibility to OMIM:[133430]
About this StructureAbout this Structure
2G44 is a Protein complex structure of sequences from Homo sapiens with T3O as ligand. Full crystallographic information is available from OCA.
ReferenceReference
Identification of ligands with bicyclic scaffolds provides insights into mechanisms of estrogen receptor subtype selectivity., Hsieh RW, Rajan SS, Sharma SK, Guo Y, DeSombre ER, Mrksich M, Greene GL, J Biol Chem. 2006 Jun 30;281(26):17909-19. Epub 2006 Apr 28. PMID:16648639
Page seeded by OCA on Mon Nov 12 22:14:19 2007